An Introduction to COPD
Multitargeted approaches to symptom relief and novel disease-targeting interventions are improving the clinical management of chronic obstructive pulmonary disorder (COPD). Recently approved fixed-triple therapy in a single inhaler reduces treatment burden, improves therapy compliance and symptom relief. Inhibiting pro-inflammatory eosinophils, valve surgery and airway tissue regeneration are currently being explored. Patient-focussed pulmonary rehabilitation strategies are offering a more holistic approach to care, improving well-being and quality of life for patients living with COPD.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Highlights From The 2020 European Respiratory Society Industry Symposium “Mind The Gap: Evidence On The Treatment Of Alpha1-Antitrypsin Deficiency And Unmet Needs”
This content is for Healthcare Professionals based in the following countries only: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Finland, Germany, Greece, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Saudi Arabia, Spain, Sweden, Switzerland and Turkey.
Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma
US Respiratory & Pulmonary Diseases. 2020;5(1):18-23 DOI: https://doi.org/10.17925/USPRD.2020.5.1.18
Strategy reports from both the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20201 and the Global Initiative for Asthma (GINA) 20192 highlight the importance of using the triple combination of inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs), and long-acting muscarinic receptor antagonists (LAMAs) in the treatment of chronic obstructive pulmonary disease (COPD) and asthma, respectively. However, there is […]
Brian Carlin, CHEST 2020 – New Thoughts in COPD
Brian Carlin (Pittsburgh Critical Care Associates, Pittsburgh, PA, US) talks to us about recent developments in the treatment of COPD and the impact COVID-19 has had on pulmonary rehabilitation services. Questions 1. What have been the most exciting recent developments in inhaled therapies for COPD? (0:20) 2. What factors should physicians consider before prescribing inhaled […]
Peter J Barnes, ERS 2020 – Smart Inhalers for COPD and Asthma
During the ERS International Congress 2020, it was great to catch up with our Editorial Board member, Prof. Peter J Barnes (Imperial College, London, UK), to continue the discussion around Smart Inhalers and how they could help optimise inhaler use in patients. Questions How common is poor adherence and inhaler technique in people with asthma […]
Henrik Hansen, ERS 2019 – Pulmonary Tele-rehabilitation Versus Conventional Rehabilitation (Part 1)
We met Henrik Hansen, from National University Hospital, Copenhagen, Denmark, at ERS 2019 to discuss his study results – 1-year follow-up of pulmonary tele-rehabilitation versus conventional pulmonary rehabilitation. Questions 1. What are the limitations of current pulmonary rehabilitation programmes? (0:05) 2. What are the potential advantages and limitations of tele-rehabilitation? (1:44) Speaker disclosures: Henrik Hansen […]
Henrik Hansen, ERS 2019 – Pulmonary Tele-rehabilitation Versus Conventional Rehabilitation (Part 2)
We met Henrik Hansen, from National University Hospital, Copenhagen, Denmark, at ERS 2019 to discuss his study results – 1-year follow-up of pulmonary tele-rehabilitation versus conventional pulmonary rehabilitation. Questions 1. Could you tell us a little about your recent clinical trial investigating tele-rehabilitation? (0:05) 2. Which patients are most likely to benefit from this approach? […]
Gerard Criner, ERS 2019 – Identification of Patients with COPD who Benefit from Benralizumab
We met with Gerard Criner, of Temple University, at ERS 2019 in Madrid, to discuss his presentation on identification of patients with chronic obstructive pulmonary disease who benefit from benralizumab. Questions 1. What is the mechanism of action of benralizumab? 2. Could you tell us a little about the aims and design of the GALATHEA […]
Peter J Barnes, ERS 2019 – COPD as a Disease of Accelerated Lung Ageing
It was delightful to speak to Editorial Board member Peter J Barnes at ERS 2019 in Madrid about chronic obstructive pulmonary disease as a disease of accelerated lung ageing. Questions 1. What are the main similarities between ageing lungs and the lungs of chronic obstructive pulmonary disease (COPD) patients? (0:07) 2. What have these similarities […]
Kirsten Almberg – Black lung, lung cancer, COPD in US coal miners
At the American Thoracic Society meeting, Dr Kirsten Almberg discussed the rise of black lung, lung cancer, and chronic obstructive pulmonary disease (COPD) in US coal miners. Here, she reiterates the results of two studies assessing mortality in US-based coal miners and the further work that needs to be done to better understand the health […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!